Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Fluvoxamine  COVID-19 treatment studies for Fluvoxamine  C19 studies: Fluvoxamine  Fluvoxamine   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 68% Improvement Relative Risk Symptom resolution 53% c19early.org/f Kirenga et al. Fluvoxamine for COVID-19 LATE Is late treatment with fluvoxamine beneficial for COVID-19? Prospective study of 316 patients in Uganda (Dec 2021 - Feb 2022) Lower mortality (p<0.0001) and improved recovery (p=0.04) Kirenga et al., Molecular Psychiatry, doi:10.1038/s41380-023-02004-3 Favors fluvoxamine Favors control
Association of fluvoxamine with mortality and symptom resolution among inpatients with COVID-19 in Uganda: a prospective interventional open-label cohort study
Kirenga et al., Molecular Psychiatry, doi:10.1038/s41380-023-02004-3
Kirenga et al., Association of fluvoxamine with mortality and symptom resolution among inpatients with COVID-19 in Uganda: a.., Molecular Psychiatry, doi:10.1038/s41380-023-02004-3
Mar 2023   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Prospective study of 316 hospitalized patients in Uganda, 94 receiving fluvoxamine, showing significantly lower mortality and improved recovery with treatment.
risk of death, 68.0% lower, HR 0.32, p < 0.001, treatment 29 of 94 (30.9%), control 126 of 222 (56.8%), NNT 3.9, adjusted for unbalanced covariates, propensity score weighting, Cox proportional hazards.
symptom resolution, 53.1% lower, HR 0.47, p = 0.04, treatment 94, control 222, inverted to make HR<1 favor treatment, propensity score weighting, Cox proportional hazards, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kirenga et al., 3 Mar 2023, prospective, Uganda, peer-reviewed, 19 authors, study period December 2021 - February 2022.
Contact: brucekirenga@yahoo.co.uk.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFluvoxamineAll
Abstract: Molecular Psychiatry ARTICLE www.nature.com/mp OPEN Association of fluvoxamine with mortality and symptom resolution among inpatients with COVID-19 in Uganda: a prospective interventional open-label cohort study ✉ Bruce J. Kirenga1,2 , Levicatus Mugenyi 2,3, Marina Sánchez-Rico 4, Henry Kyobe 5, Winters Muttamba2,6, Raymond Mugume2, 2,7 Eliya Mwesigwa , Ezra Kalimo7, Vicky Nyombi7, Ivan Segawa 2, Loryndah Olive Namakula2,7, Rogers Sekibira2, Wilberforce Kabweru7, Rosemary Byanyima7, Hellen Aanyu 7, Pauline Byakika-Kibwika 1, Henry G. Mwebesa5, Nicolas Hoertel4,8,9 and William Bazeyo10 1234567890();,: © The Author(s) 2023 Prior research suggests that fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) used for the treatment of obsessivecompulsive disorder and major depressive disorder, could be repurposed against COVID-19. We undertook a prospective interventional open-label cohort study to evaluate the efficacy and tolerability of fluvoxamine among inpatients with laboratory-confirmed COVID-19 in Uganda. The main outcome was all-cause mortality. Secondary outcomes were hospital discharge and complete symptom resolution. We included 316 patients, of whom 94 received fluvoxamine in addition to standard care [median age, 60 years (IQR = 37.0); women, 52.2%]. Fluvoxamine use was significantly associated with reduced mortality [AHR = 0.32; 95% CI = 0.19–0.53; p < 0.001, NNT = 4.46] and with increased complete symptom resolution [AOR = 2.56; 95% CI = 1.53–5.51; p < 0.001, NNT = 4.44]. Sensitivity analyses yielded similar results. These effects did not significantly differ by clinical characteristic, including vaccination status. Among the 161 survivors, fluvoxamine was not significantly associated with time to hospital discharge [AHR 0.81, 95% CI (0.54–1.23), p = 0.32]. There was a trend toward greater side effects with fluvoxamine (7.45% versus 3.15%; SMD = 0.21; χ2 = 3.46, p = 0.06), most of which were light or mild in severity and none of which were serious. One hundred mg of fluvoxamine prescribed twice daily for 10 days was well tolerated and significantly associated with reduced mortality and with increased complete symptom resolution, without a significant increase in time to hospital discharge, among inpatients with COVID-19. Large-scale randomized trials are urgently needed to confirm these findings, especially for low- and middle-income countries, where access to vaccines and approved treatments against COVID-19 is limited. Molecular Psychiatry; https://doi.org/10.1038/s41380-023-02004-3
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit